{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:39:41Z","timestamp":1792291181524,"version":"4.4.0"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40119-026-00446-8","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T16:11:54Z","timestamp":1771863114000},"page":"1-23","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Heart Failure in Kidney Transplant Recipients: Narrative Review of Risk Factors, Therapy, and Current Gaps in Management"],"prefix":"10.1007","volume":"15","author":[{"given":"Anukul","family":"Ghimire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaeth","family":"Al-Zaneen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob B.","family":"Michaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Worthen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie","family":"Rampersad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita K. S.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngan N.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Joseph","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik K.","family":"Tennankore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Vinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"issue":"9981","key":"446_CR1","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/S0140-6736(14)61601-9","volume":"385","author":"T Liyanage","year":"2015","unstructured":"Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015;385(9981):1975\u201382. https:\/\/doi.org\/10.1016\/S0140-6736(14)61601-9.","journal-title":"Lancet"},{"issue":"10","key":"446_CR2","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1111\/J.1600-6143.2011.03686.X\/ATTACHMENT\/FD03019C-28AE-4BC7-9C50-CD0C94E45723\/MMC1-SUP1-APPENDIX.DOC","volume":"11","author":"M Tonelli","year":"2011","unstructured":"Tonelli M, Wiebe N, Knoll G, et al. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant. 2011;11(10):2093\u2013109. https:\/\/doi.org\/10.1111\/J.1600-6143.2011.03686.X\/ATTACHMENT\/FD03019C-28AE-4BC7-9C50-CD0C94E45723\/MMC1-SUP1-APPENDIX.DOC.","journal-title":"Am J Transplant"},{"issue":"23","key":"446_CR3","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1056\/NEJM199912023412303","volume":"341","author":"R Wolfe","year":"1999","unstructured":"Wolfe R, Ashby V, Mildford E, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341(23):1725\u201330. https:\/\/doi.org\/10.1056\/NEJM199912023412303.","journal-title":"N Engl J Med"},{"key":"446_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(25)00222-0","author":"A Zambeli-Ljepovi\u0107","year":"2025","unstructured":"Zambeli-Ljepovi\u0107 A, Tungsanga S, Ghimire A, et al. The potential of kidney transplantation to reduce mortality from chronic kidney disease: a global, cross-sectional, modelling study. Lancet Glob Health. 2025. https:\/\/doi.org\/10.1016\/S2214-109X(25)00222-0.","journal-title":"Lancet Glob Health"},{"issue":"1","key":"446_CR5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1046\/j.1523-1755.2000.00816.x","volume":"57","author":"AO Ojo","year":"2000","unstructured":"Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK. Long-term survival in renal transplant recipients with graft function. Kidney Int. 2000;57(1):307\u201313. https:\/\/doi.org\/10.1046\/j.1523-1755.2000.00816.x.","journal-title":"Kidney Int"},{"issue":"2","key":"446_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000000640","volume":"3","author":"AK Mathur","year":"2017","unstructured":"Mathur AK, Chang YH, Steidley DE, et al. Patterns of care and outcomes in cardiovascular disease after kidney transplantation in the United States. Transplant Direct. 2017;3(2):E126. https:\/\/doi.org\/10.1097\/TXD.0000000000000640.","journal-title":"Transplant Direct"},{"issue":"3","key":"446_CR7","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/TP.0000000000001155","volume":"101","author":"NN Lam","year":"2017","unstructured":"Lam NN, Kim SJ, Knoll GA, et al. The risk of cardiovascular disease is not increasing over time despite aging and higher comorbidity burden of kidney transplant recipients. Transplantation. 2017;101(3):588\u201396. https:\/\/doi.org\/10.1097\/TP.0000000000001155.","journal-title":"Transplantation"},{"issue":"12","key":"446_CR8","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1681\/ASN.2020050566","volume":"31","author":"T Ying","year":"2020","unstructured":"Ying T, Shi B, Kelly PJ, Pilmore H, Clayton PA, Chadban SJ. Death after kidney transplantation: an analysis by era and time post-transplant. J Am Soc Nephrol. 2020;31(12):2887\u201399. https:\/\/doi.org\/10.1681\/ASN.2020050566.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"446_CR9","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1681\/ASN.V1191735","volume":"11","author":"BL Kasiske","year":"2000","unstructured":"Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol. 2000;11(9):1735\u201343. https:\/\/doi.org\/10.1681\/ASN.V1191735.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"446_CR10","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1681\/ASN.V1341084","volume":"13","author":"C Rigatto","year":"2002","unstructured":"Rigatto C, Parfrey P, Foley R, Negrijn C, Tribula C, Jeffery J. Congestive heart failure in renal transplant recipients: risk factors, outcomes, and relationship with ischemic heart disease. J Am Soc Nephrol. 2002;13(4):1084\u201390. https:\/\/doi.org\/10.1681\/ASN.V1341084.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"446_CR11","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/J.1432-2277.2010.01149.X","volume":"24","author":"AP Marcassi","year":"2011","unstructured":"Marcassi AP, Yasbek DC, Pestana JOM, et al. Ventricular arrhythmia in incident kidney transplant recipients: prevalence and associated factors. Transpl Int. 2011;24(1):67\u201372. https:\/\/doi.org\/10.1111\/J.1432-2277.2010.01149.X.","journal-title":"Transpl Int"},{"issue":"2","key":"446_CR12","doi-asserted-by":"publisher","first-page":"288","DOI":"10.2215\/CJN.00920805","volume":"1","author":"KL Lentine","year":"2006","unstructured":"Lentine KL, Schnitzler MA, Abbott KC, et al. Incidence, predictors, and associated outcomes of atrial fibrillation after kidney transplantation. Clin J Am Soc Nephrol. 2006;1(2):288\u201396. https:\/\/doi.org\/10.2215\/CJN.00920805.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"446_CR13","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1053\/j.ajkd.2005.06.019","volume":"46","author":"KL Lentine","year":"2005","unstructured":"Lentine KL, Schnitzler MA, Abbott KC, et al. De novo congestive heart failure after kidney transplantation: a common condition with poor prognostic implications. Am J Kidney Dis. 2005;46(4):720\u201333. https:\/\/doi.org\/10.1053\/j.ajkd.2005.06.019.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"446_CR14","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1111\/AJT.14702","volume":"18","author":"DA Axelrod","year":"2018","unstructured":"Axelrod DA, Schnitzler MA, Xiao H, et al. An economic assessment of contemporary kidney transplant practice. Am J Transplant. 2018;18(5):1168\u201376. https:\/\/doi.org\/10.1111\/AJT.14702.","journal-title":"Am J Transplant"},{"issue":"10","key":"446_CR15","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1016\/j.ajt.2025.05.036","volume":"25","author":"T Beaudrey","year":"2025","unstructured":"Beaudrey T, Aymes E, Thaunat O, et al. Association of delayed graft function with cardiovascular outcomes in kidney transplant recipients. Am J Transplant. 2025;25(10):2182\u201393. https:\/\/doi.org\/10.1016\/j.ajt.2025.05.036.","journal-title":"Am J Transplant"},{"issue":"5","key":"446_CR16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.123.011173","volume":"17","author":"N Bansal","year":"2024","unstructured":"Bansal N, Zelnick LR, Scherzer R, Estrella M, Shlipak MG. Risk factors and outcomes associated with heart failure with preserved and reduced ejection fraction in people with chronic kidney disease. Circ Heart Fail. 2024;17(5):E011173. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.123.011173.","journal-title":"Circ Heart Fail"},{"issue":"4","key":"446_CR17","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1097\/TP.0000000000003136","volume":"104","author":"SJ Chadban","year":"2020","unstructured":"Chadban SJ, Ahn C, Axelrod DA, et al. KDIGO clinical practice guideline on the evaluation and management of candidates for kidney transplantation. Transplantation. 2020;104(4):S11\u2013103. https:\/\/doi.org\/10.1097\/TP.0000000000003136.","journal-title":"Transplantation"},{"issue":"6","key":"446_CR18","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/J.KINT.2019.02.022","volume":"95","author":"AA House","year":"2019","unstructured":"House AA, Wanner C, Sarnak MJ, et al. Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int. 2019;95(6):1304\u201317. https:\/\/doi.org\/10.1016\/J.KINT.2019.02.022.","journal-title":"Kidney Int"},{"issue":"7","key":"446_CR19","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.4852","volume":"1","author":"M Tonelli","year":"2018","unstructured":"Tonelli M, Wiebe N, Manns BJ, et al. Comparison of the complexity of patients seen by different medical subspecialists in a universal health care system. JAMA Netw Open. 2018;1(7):e184852. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.4852.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"446_CR20","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/AJT.14018","volume":"17","author":"DA Axelrod","year":"2017","unstructured":"Axelrod DA, Schnitzler MA, Xiao H, et al. The changing financial landscape of renal transplant practice: a national cohort analysis. Am J Transplant. 2017;17(2):377\u201389. https:\/\/doi.org\/10.1111\/AJT.14018.","journal-title":"Am J Transplant"},{"issue":"18","key":"446_CR21","doi-asserted-by":"publisher","first-page":"E895","DOI":"10.1161\/CIR.0000000000001063\/FORMAT\/EPUB","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):E895\u20131032. https:\/\/doi.org\/10.1161\/CIR.0000000000001063\/FORMAT\/EPUB.","journal-title":"Circulation"},{"issue":"22","key":"446_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/JCM12226984","volume":"12","author":"S Swamy","year":"2023","unstructured":"Swamy S, Noor SM, Mathew RO. Cardiovascular disease in diabetes and chronic kidney disease. J Clin Med. 2023;12(22):6984. https:\/\/doi.org\/10.3390\/JCM12226984.","journal-title":"J Clin Med"},{"key":"446_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/S12933-018-0762-4","author":"V Ormazabal","year":"2018","unstructured":"Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zu\u00f1iga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018. https:\/\/doi.org\/10.1186\/S12933-018-0762-4.","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"446_CR24","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1111\/J.1432-2277.2008.00717.X","volume":"21","author":"J Aalten","year":"2008","unstructured":"Aalten J, Hoogeveen EK, Roodnat JI, et al. Associations between pre-kidney-transplant risk factors and post-transplant cardiovascular events and death. Transplant Int. 2008;21(10):985\u201391. https:\/\/doi.org\/10.1111\/J.1432-2277.2008.00717.X.","journal-title":"Transplant Int"},{"issue":"6","key":"446_CR25","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000001647","volume":"10","author":"Z Tian","year":"2024","unstructured":"Tian Z, Bergmann K, Kaufeld J, Schmidt-Ott K, Melk A, Schmidt BMW. Left ventricular hypertrophy after renal transplantation: systematic review and meta-analysis. Transplant Direct. 2024;10(6):e1647. https:\/\/doi.org\/10.1097\/TXD.0000000000001647.","journal-title":"Transplant Direct"},{"issue":"3","key":"446_CR26","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1681\/ASN.V133745","volume":"13","author":"P Muntner","year":"2002","unstructured":"Muntner P, He J, Hamm L, Loria C, Whelton PK. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol. 2002;13(3):745\u201353. https:\/\/doi.org\/10.1681\/ASN.V133745.","journal-title":"J Am Soc Nephrol"},{"issue":"13","key":"446_CR27","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMOA041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296\u2013305. https:\/\/doi.org\/10.1056\/NEJMOA041031.","journal-title":"N Engl J Med"},{"issue":"1","key":"446_CR28","doi-asserted-by":"publisher","first-page":"17948","DOI":"10.1038\/s41598-017-17965-z","volume":"7","author":"A Wang","year":"2017","unstructured":"Wang A, Chen G, Cao Y, et al. Estimated glomerular filtration rate, proteinuria, and risk of cardiovascular diseases and all-cause mortality in diabetic population: a community-based cohort study. Sci Rep. 2017;7(1):17948. https:\/\/doi.org\/10.1038\/s41598-017-17965-z.","journal-title":"Sci Rep"},{"issue":"4","key":"446_CR29","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1053\/AJKD.2001.27383","volume":"38","author":"WW Brown","year":"2001","unstructured":"Brown WW, Keane WF. Proteinuria and cardiovascular disease. Am J Kidney Dis. 2001;38(4):S8\u201313. https:\/\/doi.org\/10.1053\/AJKD.2001.27383.","journal-title":"Am J Kidney Dis"},{"issue":"9731","key":"446_CR30","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","volume":"375","author":"K Matsushita","year":"2010","unstructured":"Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(10)60674-5.","journal-title":"Lancet"},{"issue":"6","key":"446_CR31","doi-asserted-by":"publisher","first-page":"36077","DOI":"10.1161\/JAHA.124.036077","volume":"14","author":"JH Jeong","year":"2025","unstructured":"Jeong JH, Kim YG, Han KDo, et al. Proteinuria Is associated with an increased risk of sudden cardiac arrest in the young population. J Am Heart Assoc. 2025;14(6):36077. https:\/\/doi.org\/10.1161\/JAHA.124.036077.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"446_CR32","doi-asserted-by":"publisher","first-page":"25376","DOI":"10.1038\/s41598-024-75384-3","volume":"14","author":"HG Woo","year":"2024","unstructured":"Woo HG, Park MS, Song TJ. Persistent proteinuria is associated with the occurrence of cardiovascular disease: a nationwide population-based cohort study. Sci Rep. 2024;14(1):25376. https:\/\/doi.org\/10.1038\/s41598-024-75384-3.","journal-title":"Sci Rep"},{"issue":"4","key":"446_CR33","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.2337\/DIABETES.51.4.1157","volume":"51","author":"CDA Stehouwer","year":"2002","unstructured":"Stehouwer CDA, Gall MA, Twisk JWR, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type\u00a02 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes. 2002;51(4):1157\u201365. https:\/\/doi.org\/10.2337\/DIABETES.51.4.1157.","journal-title":"Diabetes"},{"issue":"8","key":"446_CR34","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1681\/ASN.2005121288","volume":"17","author":"CDA Stehouwer","year":"2006","unstructured":"Stehouwer CDA, Smulders YM. Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms. J Am Soc Nephrol. 2006;17(8):2106\u201311. https:\/\/doi.org\/10.1681\/ASN.2005121288.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"446_CR35","doi-asserted-by":"publisher","first-page":"E40","DOI":"10.1111\/CHF.12030","volume":"19","author":"E Alhaj","year":"2013","unstructured":"Alhaj E, Alhaj N, Rahman I, Niazi TO, Berkowitz R, Klapholz M. Uremic cardiomyopathy: an underdiagnosed disease. Congest Heart Fail. 2013;19(4):E40\u20135. https:\/\/doi.org\/10.1111\/CHF.12030.","journal-title":"Congest Heart Fail"},{"issue":"8","key":"446_CR36","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1161\/CIRCRESAHA.123.321759","volume":"132","author":"TD Nguyen","year":"2023","unstructured":"Nguyen TD, Schulze PC. Cardiac metabolism in heart failure and implications for uremic cardiomyopathy. Circ Res. 2023;132(8):1034\u201349. https:\/\/doi.org\/10.1161\/CIRCRESAHA.123.321759.","journal-title":"Circ Res"},{"issue":"5","key":"446_CR37","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1038\/ki.1996.201","volume":"49","author":"PS Parfrey","year":"1996","unstructured":"Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray D, Barre PE. Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int. 1996;49(5):1428\u201334. https:\/\/doi.org\/10.1038\/ki.1996.201.","journal-title":"Kidney Int"},{"issue":"24","key":"446_CR38","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1056\/NEJMOA1001593","volume":"363","author":"GM Chertow","year":"2010","unstructured":"Chertow GM, Levin NW, Beck GJ, et al. In-center hemodialysis six times per week versus three times per week. N Engl J Med. 2010;363(24):2287\u2013300. https:\/\/doi.org\/10.1056\/NEJMOA1001593.","journal-title":"N Engl J Med"},{"issue":"7","key":"446_CR39","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/J.JACC.2004.11.061","volume":"45","author":"RK Wali","year":"2005","unstructured":"Wali RK, Wang GS, Gottlieb SS, et al. Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease. J Am Coll Cardiol. 2005;45(7):1051\u201360. https:\/\/doi.org\/10.1016\/J.JACC.2004.11.061.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"446_CR40","doi-asserted-by":"publisher","first-page":"635","DOI":"10.7326\/0003-4819-111-8-635","volume":"111","author":"RK Burt","year":"1989","unstructured":"Burt RK, Gupta-Burt S, Suki WN, Barcenas CG, Ferguson JJ, Van Buren CT. Reversal of left ventricular dysfunction after renal transplantation. Ann Intern Med. 1989;111(8):635\u201340. https:\/\/doi.org\/10.7326\/0003-4819-111-8-635.","journal-title":"Ann Intern Med"},{"issue":"16","key":"446_CR41","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/J.JACC.2015.08.023","volume":"66","author":"N Hawwa","year":"2015","unstructured":"Hawwa N, Shrestha K, Hammadah M, Yeo PSD, Fatica R, Wilson Tang WH. Reverse remodeling and prognosis following kidney transplantation in contemporary patients with cardiac dysfunction. J Am Coll Cardiol. 2015;66(16):1779\u201387. https:\/\/doi.org\/10.1016\/J.JACC.2015.08.023.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"446_CR42","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/SDI.12313","volume":"28","author":"JC Duque","year":"2015","unstructured":"Duque JC, Gomez C, Tabbara M, et al. The impact of arteriovenous fistulae on the myocardium: the impact of creation and ligation in the transplant era. Semin Dial. 2015;28(3):305\u201310. https:\/\/doi.org\/10.1111\/SDI.12313.","journal-title":"Semin Dial"},{"issue":"10","key":"446_CR43","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1111\/J.1432-2277.2008.00707.X","volume":"21","author":"J Cridlig","year":"2008","unstructured":"Cridlig J, Selton-Suty C, Alla F, et al. Cardiac impact of the arteriovenous fistula after kidney transplantation: a case-controlled, match-paired study. Transpl Int. 2008;21(10):948\u201354. https:\/\/doi.org\/10.1111\/J.1432-2277.2008.00707.X.","journal-title":"Transpl Int"},{"issue":"25","key":"446_CR44","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1161\/CIRCULATIONAHA.118.038505","volume":"139","author":"NN Rao","year":"2019","unstructured":"Rao NN, Stokes MB, Rajwani A, et al. Effects of arteriovenous fistula ligation on cardiac structure and function in kidney transplant recipients. Circulation. 2019;139(25):2809\u201318. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038505.","journal-title":"Circulation"},{"issue":"12","key":"446_CR45","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.2215\/CJN.00520121","volume":"16","author":"KA Birdwell","year":"2021","unstructured":"Birdwell KA, Park M. Post-transplant cardiovascular disease. Clin J Am Soc Nephrol. 2021;16(12):1878\u201389. https:\/\/doi.org\/10.2215\/CJN.00520121.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"446_CR46","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1034\/j.1600-6143.2003.00010.x","volume":"3","author":"BL Kasiske","year":"2003","unstructured":"Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3(2):178\u201385. https:\/\/doi.org\/10.1034\/j.1600-6143.2003.00010.x.","journal-title":"Am J Transplant"},{"issue":"6","key":"446_CR47","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1111\/j.1523-1755.2005.00349.x","volume":"67","author":"FG Cosio","year":"2005","unstructured":"Cosio FG, Kudva Y, Van Der Velde M, et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int. 2005;67(6):2415\u201321. https:\/\/doi.org\/10.1111\/j.1523-1755.2005.00349.x.","journal-title":"Kidney Int"},{"issue":"2","key":"446_CR48","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000001433","volume":"9","author":"MT Li","year":"2023","unstructured":"Li MT, Ramakrishnan A, Yu M, et al. Effects of delayed graft function on transplant outcomes: a meta-analysis. Transplant Direct. 2023;9(2):e1433. https:\/\/doi.org\/10.1097\/TXD.0000000000001433.","journal-title":"Transplant Direct"},{"issue":"7","key":"446_CR49","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.34067\/KID.0000000773","volume":"6","author":"P Amornkanjanawat","year":"2025","unstructured":"Amornkanjanawat P, Kerr SJ, Wuttiputhanun T, et al. Kidney allograft rejection as an independent nontraditional risk factor for post-transplant cardiovascular events. Kidney360. 2025;6(7):1176\u201387. https:\/\/doi.org\/10.34067\/KID.0000000773.","journal-title":"Kidney360"},{"issue":"24","key":"446_CR50","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1056\/NEJMOA020009","volume":"349","author":"BJ Nankivell","year":"2003","unstructured":"Nankivell BJ, Borrows RJ, Fung CLS, O\u2019Connell PJ, Allen RDM, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003;349(24):2326\u201333. https:\/\/doi.org\/10.1056\/NEJMOA020009.","journal-title":"N Engl J Med"},{"issue":"5","key":"446_CR51","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1093\/NDT\/GFZ053","volume":"34","author":"J Rangaswami","year":"2019","unstructured":"Rangaswami J, Mathew RO, Parasuraman R, et al. Cardiovascular disease in the kidney transplant recipient: epidemiology, diagnosis and management strategies. Nephrol Dial Transplant. 2019;34(5):760\u201373. https:\/\/doi.org\/10.1093\/NDT\/GFZ053.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"446_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/DIAGNOSTICS14050463","volume":"14","author":"D Bedo","year":"2024","unstructured":"Bedo D, Beaudrey T, Florens N. Unraveling chronic cardiovascular and kidney disorder through the butterfly effect. Diagnostics. 2024;14(5):463. https:\/\/doi.org\/10.3390\/DIAGNOSTICS14050463.","journal-title":"Diagnostics"},{"issue":"4","key":"446_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/BIOMEDICINES13040929","volume":"13","author":"M Pittappilly","year":"2025","unstructured":"Pittappilly M, Sharshir M, Paramesh A. Chronic allograft nephropathy\u2014a narrative review of its pathogenesis, diagnosis, and evolving management strategies. Biomedicines. 2025;13(4):929. https:\/\/doi.org\/10.3390\/BIOMEDICINES13040929.","journal-title":"Biomedicines"},{"issue":"1","key":"446_CR54","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1093\/NDT\/15.1.8","volume":"15","author":"R Schindler","year":"2000","unstructured":"Schindler R, Tanriver Y, Frei U. Hypertension and allograft nephropathy\u2014cause, consequence, or both? Nephrol Dial Transplant. 2000;15(1):8\u201310. https:\/\/doi.org\/10.1093\/NDT\/15.1.8.","journal-title":"Nephrol Dial Transplant"},{"key":"446_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2024.101535","author":"MC Hill","year":"2024","unstructured":"Hill MC, Legg K, Ardati A, Groo V. Heart failure medication use and follow-up patterns in renal transplant recipients with reduced ejection fraction: a single-center experience. IJC Heart Vasc. 2024. https:\/\/doi.org\/10.1016\/j.ijcha.2024.101535.","journal-title":"IJC Heart Vasc"},{"issue":"16","key":"446_CR56","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMOA2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361. https:\/\/doi.org\/10.1056\/NEJMOA2107038.","journal-title":"N Engl J Med"},{"issue":"12","key":"446_CR57","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMOA2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089\u201398. https:\/\/doi.org\/10.1056\/NEJMOA2206286.","journal-title":"N Engl J Med"},{"issue":"11","key":"446_CR58","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJV McMurray","year":"2014","unstructured":"McMurray JJV, Packer M, Desai AS, et al. Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa1409077.","journal-title":"N Engl J Med"},{"issue":"15","key":"446_CR59","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMOA2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413\u201324. https:\/\/doi.org\/10.1056\/NEJMOA2022190.","journal-title":"N Engl J Med"},{"issue":"4","key":"446_CR60","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1681\/ASN.2021111517","volume":"33","author":"AJ Vinson","year":"2022","unstructured":"Vinson AJ, Singh S, Chadban S, et al. Premature death in kidney transplant recipients: the time for trials is now. J Am Soc Nephrol. 2022;33(4):665\u201373. https:\/\/doi.org\/10.1681\/ASN.2021111517.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"446_CR61","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S2213-8587(15)00368-X","volume":"4","author":"GA Knoll","year":"2016","unstructured":"Knoll GA, Fergusson D, Chass\u00e9 M, et al. Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2016;4(4):318\u201326. https:\/\/doi.org\/10.1016\/S2213-8587(15)00368-X.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"446_CR62","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1053\/J.AJKD.2007.04.013","volume":"50","author":"E Paoletti","year":"2007","unstructured":"Paoletti E, Cassottana P, Amidone M, Gherzi M, Rolla D, Cannella G. ACE inhibitors and persistent left ventricular hypertrophy after renal transplantation: a randomized clinical trial. Am J Kidney Dis. 2007;50(1):133\u201342. https:\/\/doi.org\/10.1053\/J.AJKD.2007.04.013.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"446_CR63","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/J.EKIR.2023.10.008","volume":"9","author":"M Charkviani","year":"2023","unstructured":"Charkviani M, Krisanapan P, Thongprayoon C, Craici IM, Cheungpasitporn W. Systematic review of cardiovascular benefits and safety of sacubitril-valsartan in end-stage kidney disease. Kidney Int Rep. 2023;9(1):39\u201351. https:\/\/doi.org\/10.1016\/J.EKIR.2023.10.008.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"446_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/S12882-022-02919-Z","volume":"23","author":"MD Mart\u00ednez-Esteban","year":"2022","unstructured":"Mart\u00ednez-Esteban MD, V\u00e1zquez-S\u00e1nchez T, Pozo-\u00c1lvarez R, et al. Cardio-renal benefits of sacubitril\/valsartan in patients with advanced chronic kidney disease: experience in daily clinical practice. BMC Nephrol. 2022;23(1):293. https:\/\/doi.org\/10.1186\/S12882-022-02919-Z.","journal-title":"BMC Nephrol"},{"issue":"1","key":"446_CR65","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1053\/j.ajkd.2016.08.018","volume":"69","author":"S Hiremath","year":"2017","unstructured":"Hiremath S, Fergusson DA, Fergusson N, Bennett A, Knoll GA. Renin-angiotensin system blockade and long-term clinical outcomes in kidney transplant recipients: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2017;69(1):78\u201386. https:\/\/doi.org\/10.1053\/j.ajkd.2016.08.018.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"446_CR66","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/J.1525-1594.1987.TB02710.X","volume":"11","author":"GF DiBona","year":"1987","unstructured":"DiBona GF. Renal innervation and denervation: lessons from renal transplantation reconsidered. Artif Organs. 1987;11(6):457\u201362. https:\/\/doi.org\/10.1111\/J.1525-1594.1987.TB02710.X.","journal-title":"Artif Organs"},{"issue":"2","key":"446_CR67","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/KI.2013.278","volume":"85","author":"N Issa","year":"2013","unstructured":"Issa N, Ortiz F, Reule SA, et al. The renin-aldosterone axis in kidney transplant recipients and its association with allograft function and structure. Kidney Int. 2013;85(2):404. https:\/\/doi.org\/10.1038\/KI.2013.278.","journal-title":"Kidney Int"},{"issue":"10","key":"446_CR68","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341(10):709\u201317. https:\/\/doi.org\/10.1056\/NEJM199909023411001.","journal-title":"N Engl J Med"},{"key":"446_CR69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313731","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014. https:\/\/doi.org\/10.1056\/NEJMoa1313731.","journal-title":"N Engl J Med"},{"issue":"10504","key":"446_CR70","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S0140-6736(25)01198-5","volume":"406","author":"M Walsh","year":"2025","unstructured":"Walsh M, Collister D, Gallagher M, et al. Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial. Lancet. 2025;406(10504):695\u2013704. https:\/\/doi.org\/10.1016\/S0140-6736(25)01198-5.","journal-title":"Lancet"},{"issue":"10505","key":"446_CR71","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S0140-6736(25)01153-5","volume":"406","author":"L Pyne","year":"2025","unstructured":"Pyne L, Rossignol P, Giles C, et al. Safety and efficacy of steroidal mineralocorticoid receptor antagonists in patients with kidney failure requiring dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2025;406(10505):811\u201320. https:\/\/doi.org\/10.1016\/S0140-6736(25)01153-5.","journal-title":"Lancet"},{"issue":"6","key":"446_CR72","doi-asserted-by":"publisher","first-page":"755","DOI":"10.2215\/CJN.0000000000000439","volume":"19","author":"LA Mortensen","year":"2024","unstructured":"Mortensen LA, Jespersen B, Helligsoe ASL, et al. Effect of spironolactone on kidney function in kidney transplant recipients (the SPIREN trial): a randomized placebo-controlled clinical trial. Clin J Am Soc Nephrol. 2024;19(6):755\u201366. https:\/\/doi.org\/10.2215\/CJN.0000000000000439.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"446_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12882-025-04161-9","volume":"26","author":"P Dibo","year":"2025","unstructured":"Dibo P, Mareddy NSR, Kojima GSA, et al. Efficacy and safety of mineralocorticoid receptor antagonists in kidney transplant patients: an updated meta-analysis of randomized controlled trials. BMC Nephrol. 2025;26(1):1\u201311. https:\/\/doi.org\/10.1186\/S12882-025-04161-9.","journal-title":"BMC Nephrol"},{"issue":"11","key":"446_CR74","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.kint.2023.10.016","volume":"10","author":"A Levin","year":"2024","unstructured":"Levin A, Ahmed SB, Carrero JJ, et al. Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;10(11):684\u2013701. https:\/\/doi.org\/10.1016\/j.kint.2023.10.016.","journal-title":"Kidney Int"},{"key":"446_CR75","doi-asserted-by":"publisher","DOI":"10.1001\/JAMA.2025.20834","author":"BL Neuen","year":"2025","unstructured":"Neuen BL, Fletcher RA, Anker SD, et al. SGLT2 inhibitors and kidney outcomes by glomerular filtration rate and albuminuria: a meta-analysis. JAMA. 2025. https:\/\/doi.org\/10.1001\/JAMA.2025.20834.","journal-title":"JAMA"},{"issue":"15","key":"446_CR76","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMOA2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346. https:\/\/doi.org\/10.1056\/NEJMOA2024816.","journal-title":"N Engl J Med"},{"issue":"8","key":"446_CR77","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1016\/j.ekir.2024.05.022","volume":"9","author":"JH Lim","year":"2024","unstructured":"Lim JH, Kwon S, Seo YJ, et al. Cardioprotective effect of SGLT2 inhibitor in diabetic kidney transplant recipients: a multicenter propensity score matched study. Kidney Int Rep. 2024;9(8):2474\u201383. https:\/\/doi.org\/10.1016\/j.ekir.2024.05.022.","journal-title":"Kidney Int Rep"},{"issue":"16","key":"446_CR78","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/J.JACC.2024.01.040","volume":"83","author":"V Kittipibul","year":"2024","unstructured":"Kittipibul V, Cox ZL, Chesdachai S, Fiuzat M, Lindenfeld JA, Mentz RJ. Genitourinary tract infections in patients taking SGLT2 inhibitors: JACC review topic of the week. J Am Coll Cardiol. 2024;83(16):1568\u201378. https:\/\/doi.org\/10.1016\/J.JACC.2024.01.040.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"446_CR79","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/J.IDC.2024.03.008","volume":"38","author":"J McAteer","year":"2024","unstructured":"McAteer J, Tamma PD. Diagnosing and managing urinary tract infections in kidney transplant recipients. Infect Dis Clin N Am. 2024;38(2):361. https:\/\/doi.org\/10.1016\/J.IDC.2024.03.008.","journal-title":"Infect Dis Clin N Am"},{"issue":"5","key":"446_CR80","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/S00592-018-1116-0","volume":"55","author":"R Puckrin","year":"2018","unstructured":"Puckrin R, Saltiel MP, Reynier P, Azoulay L, Yu OHY, Filion KB. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 2018;55(5):503\u201314. https:\/\/doi.org\/10.1007\/S00592-018-1116-0.","journal-title":"Acta Diabetol"},{"issue":"9","key":"446_CR81","doi-asserted-by":"publisher","DOI":"10.1001\/JAMANETWORKOPEN.2025.34485","volume":"8","author":"TH Cheng","year":"2025","unstructured":"Cheng TH, Lin KC, Chuang ATM, et al. SGLT2 inhibitors and external genital infection in male patients with type\u00a02 diabetes. JAMA Netw Open. 2025;8(9):e2534485-e2534485. https:\/\/doi.org\/10.1001\/JAMANETWORKOPEN.2025.34485.","journal-title":"JAMA Netw Open"},{"issue":"11","key":"446_CR82","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1111\/DOM.13820","volume":"21","author":"IC Lega","year":"2019","unstructured":"Lega IC, Bronskill SE, Campitelli MA, et al. Sodium glucose cotransporter\u00a02 inhibitors and risk of genital mycotic and urinary tract infection: a population-based study of older women and men with diabetes. Diabetes Obes Metab. 2019;21(11):2394\u2013404. https:\/\/doi.org\/10.1111\/DOM.13820.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"446_CR83","doi-asserted-by":"publisher","first-page":"945","DOI":"10.2337\/DC24-2169","volume":"48","author":"C Ljungberg","year":"2025","unstructured":"Ljungberg C, Kristensen FPB, Dalager-Pedersen M, et al. Risk of urogenital infections in people with type\u00a02 diabetes initiating SGLT2is versus GLP-1RAs in routine clinical care: a Danish cohort study. Diabetes Care. 2025;48(6):945\u201354. https:\/\/doi.org\/10.2337\/DC24-2169.","journal-title":"Diabetes Care"},{"issue":"4","key":"446_CR84","doi-asserted-by":"publisher","first-page":"248","DOI":"10.7326\/M18-3136","volume":"171","author":"CV Dave","year":"2019","unstructured":"Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study. Ann Intern Med. 2019;171(4):248\u201356. https:\/\/doi.org\/10.7326\/M18-3136.","journal-title":"Ann Intern Med"},{"key":"446_CR85","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000951","author":"VS Sridhar","year":"2025","unstructured":"Sridhar VS, Kugathasan L, Lytvyn Y, et al. Efficacy, mechanisms and safety of sodium-glucose cotransporter-2 inhibitors in kidney transplant recipients: a randomized, double-blind, placebo-controlled trial. Clin J Am Soc Nephrol. 2025. https:\/\/doi.org\/10.2215\/CJN.0000000951.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"446_CR86","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.ekir.2024.11.033","volume":"10","author":"L Maigret","year":"2025","unstructured":"Maigret L, Basle L, Chatelet V, et al. Sodium-glucose cotransporter-2 inhibitor in diabetic and nondiabetic renal transplant recipients. Kidney Int Rep. 2025;10(3):816\u201327. https:\/\/doi.org\/10.1016\/j.ekir.2024.11.033.","journal-title":"Kidney Int Rep"},{"issue":"26","key":"446_CR87","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1182\/BLOOD.2021013996","volume":"138","author":"N Gangat","year":"2021","unstructured":"Gangat N, Szuber N, Alkhateeb H, Al-Kali A, Pardanani A, Tefferi A. JAK2 wild-type erythrocytosis associated with sodium-glucose cotransporter\u00a02 inhibitor therapy. Blood. 2021;138(26):2886\u20139. https:\/\/doi.org\/10.1182\/BLOOD.2021013996.","journal-title":"Blood"},{"issue":"7","key":"446_CR88","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.123.010613","volume":"16","author":"M Tukker","year":"2023","unstructured":"Tukker M, Bruwiere E, Bos S, Caliskan K. SGLT2 inhibitor-related polycythemia in a patient with chronic heart failure: a potential severe adverse event. Circ Heart Fail. 2023;16(7):E010613. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.123.010613.","journal-title":"Circ Heart Fail"},{"issue":"1","key":"446_CR89","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMOA1208500","volume":"368","author":"R Marchioli","year":"2013","unstructured":"Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22\u201333. https:\/\/doi.org\/10.1056\/NEJMOA1208500.","journal-title":"N Engl J Med"},{"issue":"8","key":"446_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(23)03123-6","volume":"81","author":"A Rao","year":"2023","unstructured":"Rao A, Rao LG, Parekh A, Tait D, DeYoung MB. Blood is thicker than water: polycythemia vera induced high output heart failure. J Am Coll Cardiol. 2023;81(8):2679. https:\/\/doi.org\/10.1016\/S0735-1097(23)03123-6.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"446_CR91","doi-asserted-by":"publisher","first-page":"220","DOI":"10.5500\/WJT.V11.I6.220","volume":"11","author":"B Alzoubi","year":"2021","unstructured":"Alzoubi B, Kharel A, Machhi R, Aziz F, Swanson KJ, Parajuli S. Post-transplant erythrocytosis after kidney transplantation: a review. World J Transplant. 2021;11(6):220. https:\/\/doi.org\/10.5500\/WJT.V11.I6.220.","journal-title":"World J Transplant"},{"key":"446_CR92","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.112.000091","author":"W Aftab","year":"2013","unstructured":"Aftab W, Varadarajan P, Rasool S, Kore A, Pai RG. Beta and angiotensin blockades are associated with improved 10-year survival in renal transplant recipients. J Am Heart Assoc. 2013. https:\/\/doi.org\/10.1161\/JAHA.112.000091.","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"446_CR93","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/S0735-1097(03)00241-9","volume":"41","author":"G Cice","year":"2003","unstructured":"Cice G, Ferrara L, D\u2019Andrea A, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol. 2003;41(9):1438\u201344. https:\/\/doi.org\/10.1016\/S0735-1097(03)00241-9.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"446_CR94","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1001\/ARCHINTE.164.22.2465","volume":"164","author":"KC Abbott","year":"2004","unstructured":"Abbott KC, Trespalacios FC, Agodoa LY, Taylor AJ, Bakris GL. \u03b2-Blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. Arch Intern Med. 2004;164(22):2465\u201371. https:\/\/doi.org\/10.1001\/ARCHINTE.164.22.2465.","journal-title":"Arch Intern Med"},{"issue":"3","key":"446_CR95","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/NDT\/GFT515","volume":"29","author":"R Agarwal","year":"2014","unstructured":"Agarwal R, Sinha AD, Pappas MK, Abraham TN, Tegegne GG. Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. Nephrol Dial Transplant. 2014;29(3):672\u201381. https:\/\/doi.org\/10.1093\/NDT\/GFT515.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"446_CR96","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1001\/ARCHSURG.2011.1698","volume":"147","author":"S Kwon","year":"2012","unstructured":"Kwon S, Thompson R, Florence M, et al. \u03b2-blocker continuation after noncardiac surgery: a report from the surgical care and outcomes assessment program. Arch Surg. 2012;147(5):467\u201373. https:\/\/doi.org\/10.1001\/ARCHSURG.2011.1698.","journal-title":"Arch Surg"},{"issue":"1","key":"446_CR97","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1067\/MHJ.2001.111547","volume":"141","author":"JB Shammash","year":"2001","unstructured":"Shammash JB, Trost JC, Gold JM, Berlin JA, Golden MA, Kimmel SE. Perioperative \u03b2-blocker withdrawal and mortality in vascular surgical patients. Am Heart J. 2001;141(1):148\u201353. https:\/\/doi.org\/10.1067\/MHJ.2001.111547.","journal-title":"Am Heart J"},{"issue":"6","key":"446_CR98","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1345\/APH.18356","volume":"33","author":"MF Hebert","year":"1999","unstructured":"Hebert MF, Lam AY. Diltiazem increases tacrolimus concentrations. Ann Pharmacother. 1999;33(6):680\u20132. https:\/\/doi.org\/10.1345\/APH.18356.","journal-title":"Ann Pharmacother"},{"issue":"3","key":"446_CR99","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.rec.2024.09.008","volume":"78","author":"MD Garc\u00eda-Cos\u00edo","year":"2025","unstructured":"Garc\u00eda-Cos\u00edo MD, Cruzado JM, Farrero M, et al. Management of heart disease in renal transplant recipients: a national Delphi survey-based SET\/SEC\/SEN consensus document. Rev Esp Cardiol (Engl Ed). 2025;78(3):252\u201362. https:\/\/doi.org\/10.1016\/j.rec.2024.09.008.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"446_CR100","doi-asserted-by":"publisher","DOI":"10.1002\/EHF2.70008","author":"CH Ma","year":"2025","unstructured":"Ma CH, Qi A, Gagnon L, et al. Therapy gaps for patients with heart failure and reduced kidney function: a prospective cohort study. ESC Heart Fail. 2025. https:\/\/doi.org\/10.1002\/EHF2.70008.","journal-title":"ESC Heart Fail"},{"issue":"3","key":"446_CR101","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMOA1410853","volume":"372","author":"MR Weir","year":"2015","unstructured":"Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015;372(3):211\u201321. https:\/\/doi.org\/10.1056\/NEJMOA1410853.","journal-title":"N Engl J Med"},{"issue":"3","key":"446_CR102","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1056\/NEJMOA1411487","volume":"372","author":"DK Packham","year":"2015","unstructured":"Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med. 2015;372(3):222\u201331. https:\/\/doi.org\/10.1056\/NEJMOA1411487.","journal-title":"N Engl J Med"},{"key":"446_CR103","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.mayocp.2019.05.019","volume":"95","author":"BF Palmer","year":"2020","unstructured":"Palmer BF. Potassium binders for hyperkalemia in chronic kidney diseased\u2014diet, renin-angiotensin-aldosterone system inhibitor therapy, and hemodialysis. Mayo Clin Proc. 2020;95:339\u201354. https:\/\/doi.org\/10.1016\/j.mayocp.2019.05.019.","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"446_CR104","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/J.JACC.2024.11.014","volume":"85","author":"MN Kosiborod","year":"2025","unstructured":"Kosiborod MN, Cherney DZI, Desai AS, et al. Sodium zirconium cyclosilicate for management of hyperkalemia during spironolactone optimization in patients with heart failure. J Am Coll Cardiol. 2025;85(10):971\u201384. https:\/\/doi.org\/10.1016\/J.JACC.2024.11.014.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"446_CR105","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/S40119-022-00289-Z","volume":"12","author":"NL Lariv\u00e9e","year":"2023","unstructured":"Lariv\u00e9e NL, Michaud JB, More KM, Wilson JA, Tennankore KK. Hyperkalemia: prevalence, predictors and emerging treatments. Cardiol Ther. 2023;12(1):35\u201363. https:\/\/doi.org\/10.1007\/S40119-022-00289-Z.","journal-title":"Cardiol Ther"},{"issue":"31","key":"446_CR106","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/EURHEARTJ\/EHT187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34(31):2453\u201363. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHT187.","journal-title":"Eur Heart J"},{"issue":"23","key":"446_CR107","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMOA2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type\u00a02 diabetes. N Engl J Med. 2020;383(23):2219\u201329. https:\/\/doi.org\/10.1056\/NEJMOA2025845.","journal-title":"N Engl J Med"},{"issue":"24","key":"446_CR108","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMOA2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type\u00a02 diabetes. N Engl J Med. 2021;385(24):2252\u201363. https:\/\/doi.org\/10.1056\/NEJMOA2110956.","journal-title":"N Engl J Med"},{"issue":"16","key":"446_CR109","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMOA2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024;391(16):1475\u201385. https:\/\/doi.org\/10.1056\/NEJMOA2407107.","journal-title":"N Engl J Med"},{"issue":"3","key":"446_CR110","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2215\/CJN.0000000000000300","volume":"19","author":"BF Palmer","year":"2024","unstructured":"Palmer BF, Clegg DJ. SGLT2 inhibition and kidney potassium homeostasis. Clin J Am Soc Nephrol. 2024;19(3):399\u2013405. https:\/\/doi.org\/10.2215\/CJN.0000000000000300.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"19","key":"446_CR111","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","volume":"145","author":"BL Neuen","year":"2022","unstructured":"Neuen BL, Oshima M, Agarwal R, et al. Sodium-glucose cotransporter\u00a02 inhibitors and risk of hyperkalemia in people with type\u00a02 diabetes: a meta-analysis of individual participant data from randomized, controlled trials. Circulation. 2022;145(19):1460\u201370. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.057736.","journal-title":"Circulation"},{"issue":"12","key":"446_CR112","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1681\/ASN.0000000000000248","volume":"34","author":"RA Fletcher","year":"2023","unstructured":"Fletcher RA, Jongs N, Chertow GM, et al. Effect of SGLT2 inhibitors on discontinuation of renin\u2013angiotensin system blockade: a joint analysis of the CREDENCE and DAPA-CKD trials. J Am Soc Nephrol. 2023;34(12):1965\u201375. https:\/\/doi.org\/10.1681\/ASN.0000000000000248.","journal-title":"J Am Soc Nephrol"},{"key":"446_CR113","unstructured":"ClinicalTrials.gov. The EFFECT of FinErenone in Kidney TransplantiOn Recipients: the EFFEKTOR study."},{"issue":"9","key":"446_CR114","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1093\/NDT\/GFAF046","volume":"40","author":"WM Bakker","year":"2025","unstructured":"Bakker WM, Heerspink HJL, Berger SP, et al. Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease. Nephrol Dial Transplant. 2025;40(9):1746. https:\/\/doi.org\/10.1093\/NDT\/GFAF046.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"446_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/J.TRRE.2025.100963","volume":"39","author":"M Ortved","year":"2025","unstructured":"Ortved M, Dagn\u00e6s-Hansen J, Stroomberg HV, Rohrsted M, S\u00f8rensen SS, R\u00f8der A. Early surgical complications following kidney transplantation in adults: a systematic review. Transplant Rev. 2025;39(4):100963. https:\/\/doi.org\/10.1016\/J.TRRE.2025.100963.","journal-title":"Transplant Rev"},{"key":"446_CR116","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz233","author":"A Ghimire","year":"2019","unstructured":"Ghimire A, Fine N, Ezekowitz JA, Howlett J, Youngson E, McAlister FA. Frequency, predictors, and prognosis of ejection fraction improvement in heart failure: an echocardiogram-based registry study. Eur Heart J. 2019. https:\/\/doi.org\/10.1093\/eurheartj\/ehz233.","journal-title":"Eur Heart J"},{"issue":"10166","key":"446_CR117","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(18)32484-X","volume":"393","author":"BP Halliday","year":"2019","unstructured":"Halliday BP, Wassall R, Lota AS, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet. 2019;393(10166):61\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(18)32484-X.","journal-title":"Lancet"},{"key":"446_CR118","doi-asserted-by":"publisher","unstructured":"Iyalomhe OE, Saparamadu AADNS, Alexander GC. Use of statins for primary prevention among individuals with CKD in the United States: a cross-sectional, time-trend analysis. Am J Kidney Dis. 2025;85(4):421\u2013431.e1. https:\/\/doi.org\/10.1053\/j.ajkd.2024.11.003.","DOI":"10.1053\/j.ajkd.2024.11.003"},{"issue":"5","key":"446_CR119","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1097\/TP.0B013E31820437BD","volume":"91","author":"HL Pilmore","year":"2011","unstructured":"Pilmore HL, Skeans MA, Snyder JJ, Israni AK, Kasiske BL. Cardiovascular disease medications after renal transplantation: results from the patient outcomes in renal transplantation study. Transplantation. 2011;91(5):542\u201351. https:\/\/doi.org\/10.1097\/TP.0B013E31820437BD.","journal-title":"Transplantation"},{"key":"446_CR120","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.124.012357","author":"JA Jacobs","year":"2025","unstructured":"Jacobs JA, Ayodele I, Bress AP, et al. Social determinants of health and disparities in guideline-directed medical therapy optimization for heart failure. Circ Heart Fail. 2025. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.124.012357.","journal-title":"Circ Heart Fail"},{"issue":"21","key":"446_CR121","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1161\/CIRCULATIONAHA.122.059032","volume":"146","author":"M Tonelli","year":"2022","unstructured":"Tonelli M, Straus S. Increasing societal benefit from cardiovascular drugs. Circulation. 2022;146(21):1627\u201335. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.059032.","journal-title":"Circulation"},{"issue":"4","key":"446_CR122","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1053\/j.ajkd.2025.01.006","volume":"85","author":"A Ghimire","year":"2025","unstructured":"Ghimire A, Wanner C, Tonelli M. Closing CKD treatment gaps: why practice guidelines and better drug coverage are not enough. Am J Kidney Dis. 2025;85(4):406\u20138. https:\/\/doi.org\/10.1053\/j.ajkd.2025.01.006.","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"446_CR123","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1592\/PHCO.20.9.823.35205","volume":"20","author":"SH Simpson","year":"2000","unstructured":"Simpson SH, Farris KB, Johnson JA, Tsuyuki RT. Using focus groups to identify barriers to drug use in patients with congestive heart failure. Pharmacotherapy. 2000;20(7):823\u20139. https:\/\/doi.org\/10.1592\/PHCO.20.9.823.35205.","journal-title":"Pharmacotherapy"},{"issue":"5","key":"446_CR124","doi-asserted-by":"publisher","first-page":"324","DOI":"10.4212\/cjhp.v71i5.2843","volume":"71","author":"S Sam","year":"2018","unstructured":"Sam S, Gu\u00e9rin A, Rieutord A, Belaiche S, Bussi\u00e8res JF. Roles and impacts of the transplant pharmacist: a systematic review. Can J Hosp Pharm. 2018;71(5):324. https:\/\/doi.org\/10.4212\/cjhp.v71i5.2843.","journal-title":"Can J Hosp Pharm"},{"key":"446_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/J.JACADV.2023.100289","author":"MP Dorsch","year":"2023","unstructured":"Dorsch MP, Sifuentes A, Cordwin DJ, et al. A computable algorithm for medication optimization in heart failure with reduced ejection fraction. JACC Adv. 2023. https:\/\/doi.org\/10.1016\/J.JACADV.2023.100289.","journal-title":"JACC Adv"},{"issue":"5","key":"446_CR126","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1161\/CIRCULATIONAHA.120.051863","volume":"143","author":"LA Allen","year":"2021","unstructured":"Allen LA, Venechuk G, McIlvennan CK, et al. An electronically delivered patient-activation tool for intensification of medications for chronic heart failure with reduced ejection fraction: the EPIC-HF trial. Circulation. 2021;143(5):427\u201337. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.051863.","journal-title":"Circulation"},{"issue":"1","key":"446_CR127","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41746-020-0221-y","volume":"3","author":"RT Sutton","year":"2020","unstructured":"Sutton RT, Pincock D, Baumgart DC, Sadowski DC, Fedorak RN, Kroeker KI. An overview of clinical decision support systems: benefits, risks, and strategies for success. npj Digit Med. 2020;3(1):17. https:\/\/doi.org\/10.1038\/s41746-020-0221-y.","journal-title":"npj Digit Med"},{"issue":"11","key":"446_CR128","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.009353","volume":"15","author":"VN Rao","year":"2022","unstructured":"Rao VN, Mentz RJ, Coniglio AC, et al. Neighborhood socioeconomic disadvantage and hospitalized heart failure outcomes in the American Heart Association Get with the Guidelines-Heart Failure Registry. Circ Heart Fail. 2022;15(11):E009353. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.121.009353.","journal-title":"Circ Heart Fail"},{"key":"446_CR129","doi-asserted-by":"publisher","DOI":"10.1177\/20543581221081207","author":"L Dubrofsky","year":"2022","unstructured":"Dubrofsky L, Lee JF, Hajimirzarahimshirazi P, et al. A unique multi- and interdisciplinary cardiology-renal-endocrine clinic: a description and assessment of outcomes. Can J Kidney Health Dis. 2022. https:\/\/doi.org\/10.1177\/20543581221081207.","journal-title":"Can J Kidney Health Dis"},{"issue":"1","key":"446_CR130","doi-asserted-by":"publisher","first-page":"83","DOI":"10.4997\/JRCPE.2017.118","volume":"47","author":"J Spaak","year":"2017","unstructured":"Spaak J. Novel combined management approaches to patients with diabetes, chronic kidney disease and cardiovascular disease. J R Coll Physicians Edinb. 2017;47(1):83\u20137. https:\/\/doi.org\/10.4997\/JRCPE.2017.118.","journal-title":"J R Coll Physicians Edinb"},{"key":"446_CR131","doi-asserted-by":"publisher","DOI":"10.1093\/NDT\/GFR292","author":"C Weber","year":"2012","unstructured":"Weber C, Beaulieu M, Djurdjev O, et al. Towards rational approaches of health care utilization in complex patients: an exploratory randomized trial comparing a novel combined clinic to multiple specialty clinics in patients with renal disease-cardiovascular disease-diabetes. Nephrol Dial Transplant. 2012. https:\/\/doi.org\/10.1093\/NDT\/GFR292.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"446_CR132","doi-asserted-by":"publisher","first-page":"749","DOI":"10.34067\/KID.0000602022\/-\/DCSUPPLEMENTAL","volume":"3","author":"N Bansal","year":"2022","unstructured":"Bansal N, Arora N, Mariuma D, Jefferson JA, O\u2019brien K, Shankland S. Mission and 1-year outcomes of a cardiorenal subspecialty consultation service. Kidney360. 2022;3(4):749\u201351. https:\/\/doi.org\/10.34067\/KID.0000602022\/-\/DCSUPPLEMENTAL.","journal-title":"Kidney360"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00446-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-026-00446-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00446-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T17:26:27Z","timestamp":1773509187000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-026-00446-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":132,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["446"],"URL":"https:\/\/doi.org\/10.1007\/s40119-026-00446-8","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"19 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Karthik Tennankore has conducted advisory board work with Otsuka Canada, and received grant support for an investigator-initiated project. Karthik Tennankore has also conducted advisory board work for Virtual Hallway. S. Joseph Kim is a member of the Data Monitoring Committee of a clinical trial sponsored by Eledon Pharmaceuticals to test a novel kidney transplant therapeutic. Sunita K. Singh has received dapagliflozin and matching placebo from AstraZeneca for an investigator-initiated study. Anukul Ghimire, Gaeth Al-Zaneen, Jacob B. Michaud, George Worthen, Christie Rampersad, Ngan N. Lam, and Amanda Vinson have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}